DNA methylation of membrane‐bound catechol‐O‐methyltransferase in Malaysian schizophrenia patients

Huda, Abd Rahim Nour El; Norsidah, Ku Zaifah; Fikri, Mohd Rahim Nabil; Hanisah, Mohd Noor; Abdullah, Khaizuran; Talib, Norlelawati A.

doi:10.1111/pcn.12622

Cited by 23 publications

(20 citation statements)

References 52 publications

(118 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 78 The role of DNA methylation in other mental disorders has also been explored. For example, the methylation level of catechol-O-methyl transferase in peripheral blood was lower in patients with schizophrenia (SZ) than in healthy controls in a Malaysian study, 79 which seemed to be affected by the severity of the clinical symptoms as well as the pharmacological treatment. 79 Moreover, crosstalk between different epigenetic signals including DNA methylation, histone modifications, and micro RNAs was also suggested in the development of SZ.…”

Section: Dna Methylation and Common Diseasesmentioning

confidence: 99%

“…For example, the methylation level of catechol-O-methyl transferase in peripheral blood was lower in patients with schizophrenia (SZ) than in healthy controls in a Malaysian study, 79 which seemed to be affected by the severity of the clinical symptoms as well as the pharmacological treatment. 79 Moreover, crosstalk between different epigenetic signals including DNA methylation, histone modifications, and micro RNAs was also suggested in the development of SZ. 80 , 81 In addition, some genome-wide studies found that differentially methylated CpGs are strongly related to the development of Parkinson's disease (PD), either from the cerebral cortex, 82 or from blood and saliva.…”

Section: Dna Methylation and Common Diseasesmentioning

confidence: 99%

See 1 more Smart Citation

DNA methylation in human diseases

2018

View full text Add to dashboard Cite

Even though the importance of epigenetics was first recognized in light of its role in tissue development, an increasing amount of evidence has shown that it also plays an important role in the development and progression of many common diseases. We discuss some recent findings on one representative epigenetic modification, DNA methylation, in some common diseases. While many new risk factors have been identified through the population-based epigenetic epidemiologic studies on the role of epigenetics in common diseases, this relatively new field still faces many unique challenges. Here, we describe those promises and unique challenges of epigenetic epidemiological studies and propose some potential solutions.

show abstract

Section: Dna Methylation and Common Diseasesmentioning

confidence: 99%

Section: Dna Methylation and Common Diseasesmentioning

confidence: 99%

DNA methylation in human diseases

2018

View full text Add to dashboard Cite

show abstract

“…Our systematic review yielded 29 studies (Table 1). Eighteen studies analyzed methylation in patients with schizophrenia, four studies in patients with bipolar disorder, and seven studies in a combined sample of patients with schizophrenia and bipolar disorder. The majority (n=22) of studies included observational sampling, such as cross‐sectional or case‐control studies, and the remaining analyzed changes in a prospective manner.…”

Section: Resultsmentioning

confidence: 99%

“…Two studies identified increased COMT methylation; the first in patients with schizophrenia on antipsychotics compared to healthy controls and the second in patients with schizophrenia with metabolic syndrome . In contrast, two studies found decreased COMT methylation in patients with schizophrenia versus controls and furthermore, in one study, lower methylation was also specifically associated with atypical antipsychotic treatment . 5‐HTT findings were also mixed with one study finding decreased methylation with long‐term antipsychotic use whereas another study found no differences .…”

Section: Discussionmentioning

confidence: 98%

“…The most commonly employed measurement utilized restriction enzymes (five studies) followed by transposable elements (two studies) and ELISA (one study). 26 Obs 133 SCZ AAP and TAP Blood Global Cheng et al 27 Obs and prosp 30 Obs 172 BD olanzapine and quetiapine Blood d EWAS and genespecific Kinoshita et al 31 Prosp 21 SCZ olanzapine Blood EWAS Li et al 32 Obs 92 SCZ; 99 BD; 92 HC AAP and TAP Blood global Lott et al 33 Obs 85 SCZ NR blood gene-specific Melas et al 34 Obs 177 SCZ; 171 HC AAP and TAP Blood Global and genespecific Mill et al 35 Obs 35 SZ; 35 BD; 35 HC NR Brain EWAS Miura et al 36 Prosp 34 SCZ risperidone Blood Gene-specific Moons et al 37 Obs 438 SCZ AAP and TAP Blood Gene-specific Nour El Huda et al 38 Obs 138 SCZ; 132 HC AAP and TAP Blood Gene-specific Rukova et al 39 Prosp 20 SCZ; 220 HC NR Blood EWAS Shi et al 40 Prosp 288 SCZ risperidone Blood Gene-specific Swathy et al 41 Obs 184 SCZ; 330 HC NR Blood Global Tang et al 42 Prosp 82 SCZ AAP and TAP Blood Gene-specific Venugopal et al 43 Prosp 47 SCZ; 47 HC AAP Blood Gene-specific Zong et al 44 Obs 279 SCZ; 265 HC AAP and TAP Blood Gene-specific Details of 29 studies included in the systematic review including study design, type of antipsychotic within study, sample type for DNA methylation analysis, and overall DNA methylation strategy. AAP = atypical antipsychotic; BD = bipolar disorder; HC = healthy control; MDD = major depressive disorder; NR = not reported; obs = observational; PR = primary relative; pros = prospective; scz = schizophrenia; TAP = typical antipsychotic; UPR = unaffected primary relative.…”

Section: Global Methylation Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Antipsychotic Medications and DNA Methylation in Schizophrenia and Bipolar Disorder: A Systematic Review

et al. 2020

View full text Add to dashboard Cite

The pharmacoepigenetics of antipsychotic treatment in severe mental illness is a growing area of research that aims to understand the interface between antipsychotic treatment and genetic regulation. Pharmacoepigenetics may some day assist in identifying treatment response mechanisms or become one of the components in the implementation of precision medicine. To understand the current evidence regarding the effects of antipsychotics on DNA methylation a systematic review with qualitative synthesis was performed through Pubmed, Embase and Psychinfo from earliest data to June 2019. Studies were included if they analyzed DNA methylation in an antipsychotic‐treated population of patients with schizophrenia or bipolar disorder. Data extraction occurred via a standardized format and study quality was assessed. Twenty‐nine studies were identified for inclusion. Study design, antipsychotic type, sample source, and methods of DNA methylation measurement varied across all studies. Eighteen studies analyzed methylation in patients with schizophrenia, four studies in patients with bipolar disorder, and seven studies in a combined sample of schizophrenia and bipolar disorder. Twenty‐two studies used observational samples whereas the remainder used prospectively treated samples. Six studies assessed global methylation, five assessed epigenome‐wide, and 15 performed a candidate epigenetic study. Two studies analyzed both global and gene‐specific methylation, whereas one study performed a simultaneous epigenome‐wide and gene‐specific study. Only three genes were analyzed in more than one gene‐specific study and the findings were discordant. The state of the pharmacoepigenetic literature on antipsychotic use is still in its early stages and uniform reporting of methylation site information is needed. Future work should concentrate on using prospective sampling with appropriate control groups and begin to replicate many of the novel associations that have been reported.

show abstract

YBX1‐Mediated DNA Methylation‐Dependent SHANK3 Expression in PBMCs and Developing Cortical Interneurons in Schizophrenia

Zhou

Liang

et al. 2023

Advanced Science

View full text Add to dashboard Cite

Schizophrenia (SCZ) is a severe psychiatric and neurodevelopmental disorder. The pathological process of SCZ starts early during development, way before the first onset of psychotic symptoms. DNA methylation plays an important role in regulating gene expression and dysregulated DNA methylation is involved in the pathogenesis of various diseases. The methylated DNA immunoprecipitation‐chip (MeDIP‐chip) is performed to investigate genome‐wide DNA methylation dysregulation in peripheral blood mononuclear cells (PBMCs) of patients with first‐episode SCZ (FES). Results show that the SHANK3 promoter is hypermethylated, and this hypermethylation (HyperM) is negatively correlated with the cortical surface area in the left inferior temporal cortex and positively correlated with the negative symptom subscores in FES. The transcription factor YBX1 is further found to bind to the HyperM region of SHANK3 promoter in induced pluripotent stem cells (iPSCs)‐derived cortical interneurons (cINs) but not glutamatergic neurons. Furthermore, a direct and positive regulatory effect of YBX1 on the expression of SHANK3 is confirmed in cINs using shRNAs. In summary, the dysregulated SHANK3 expression in cINs suggests the potential role of DNA methylation in the neuropathological mechanism underlying SCZ. The results also suggest that HyperM of SHANK3 in PBMCs can serve as a potential peripheral biomarker of SCZ.

show abstract

DNA methylation of membrane‐bound catechol‐O‐methyltransferase in Malaysian schizophrenia patients

Cited by 23 publications

References 52 publications

DNA methylation in human diseases

DNA methylation in human diseases

Antipsychotic Medications and DNA Methylation in Schizophrenia and Bipolar Disorder: A Systematic Review

YBX1‐Mediated DNA Methylation‐Dependent SHANK3 Expression in PBMCs and Developing Cortical Interneurons in Schizophrenia

Contact Info

Product

Resources

About